In Brief: ThermoTrex Corp.
This article was originally published in The Gray Sheet
Executive Summary
ThermoTrex Corp.: Mammography and stereotactic needle biopsy manufacturer names Gary Weinstein chairman and CEO effective Feb. 26. Weinstein, presently head of Lehman Brothers' global syndicate and equity capital markets group, will fill posts held by Firooz Rufeh, who will remain in the positions of president of ThermoTrex and VP of parent company Thermo Electron. Weinstein also is named a VP of Thermo Electron. Rufeh, who oversaw ThermoTrex' 1991 initial public offering as well as the 1994 IPO of its ThermoLase subsidiary, will "concentrate on strategic planning, technology development, and acquisitions for ThermoTrex and Thermo Electron," according to a release...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.